Related Experiment Video
Updated: May 16, 2025
05:57
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
636
Effectiveness of Xuanshen Yishen Decoction on Intensive Blood Pressure Control: Emulation of a Randomized Target
Xiao-Jie Wang1,2, Yuan-Long Hu2, Jia-Ming Huan2
1Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, 999078, China.
Chinese Journal of Integrative Medicine
|May 15, 2025
Summary
Xuanshen Yishen Decoction (XYD) improved intensive blood pressure (BP) control and reduced hospital readmissions in hypertensive patients. This study provides real-world evidence for complementary therapies in hypertension management.
Area of Science:
- Cardiovascular Medicine
- Integrative Medicine
- Pharmacology
Background:
- Hypertension remains a significant global health challenge, necessitating novel therapeutic strategies.
- Traditional Chinese Medicine (TCM) offers potential complementary approaches for managing complex conditions like hypertension.
- Xuanshen Yishen Decoction (XYD) is a TCM formulation with potential antihypertensive properties.
Purpose of the Study:
- To evaluate the clinical effectiveness of Xuanshen Yishen Decoction (XYD) as an add-on therapy for hypertension.
- To assess XYD's impact on achieving intensive blood pressure (BP) control and reducing 6-month all-cause readmission rates.
Main Methods:
- A pragmatic clinical trial design was emulated using hospital electronic medical records (2019-2023).
- Eligible participants (age ≥40, systolic BP ≥140 mm Hg) were divided into a treatment group (XYD + antihypertensive regimen) and a control group (antihypertensive regimen only).
- Primary outcome: attainment rate of intensive BP control at discharge; Secondary outcome: 6-month all-cause readmission rate.
Main Results:
- The study included 3,302 patients (359 in treatment, 2,943 in control).
- The XYD group showed a significantly higher rate of intensive BP control (17.5% vs. 8.09%, OR=2.29, P<0.001), especially in those with high homocysteine levels.
- The 6-month all-cause readmission rate was lower in the XYD group (HR=0.58, P=0.019), with robust findings confirmed by sensitivity analyses.
Conclusions:
- Xuanshen Yishen Decoction (XYD) demonstrates potential as a complementary therapy for enhancing intensive BP control in hypertensive patients.
- The findings support XYD's role in reducing hospital readmissions, offering valuable real-world evidence for integrative treatment strategies.
- This research guides the selection of complementary and alternative therapies for hypertension management.
Keywords:
6-month all-cause readmission rateXuanshen Yishen Decoctionhypertensionintensive blood pressure controlreal-world datatarget trial emulationMore Related Videos
Related Concept Videos
01:25Errors occurring during blood pressure monitoring
573
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
573
01:16Antihypertensive Drugs: Action of Diuretics
588
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
588
01:25Antihypertensive Drugs: Direct Renin Inhibitors
454
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
454
01:18Hypertension and Regulation of Blood Pressure
1.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
01:30Blood Pressure
922
Blood pressure (BP) is the pressure or force of blood exerted on the artery's walls as it circulates through the body. It is essential for maintaining blood flow throughout the body.
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
922
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329